Exisulind
Code | Size | Price |
---|
TAR-T24051-5mg | 5mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24051-1mL | 1 mL * 10 mM (in DMSO) | £112.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24051-10mg | 10mg | £135.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24051-25mg | 25mg | £201.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24051-50mg | 50mg | £266.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24051-100mg | 100mg | £359.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Exisulind induces apoptosis through the activation of protein kinase G (PKG). Exisulind exhibits antineoplastic activity in solid tumour and haematological cancer cell lines and is an inhibitor of tumour growth in rodent models of colon, prostate, bladder, mammary and lung cancer.
CAS:
59973-80-7
Formula:
C20H17FO4S
Molecular Weight:
372.41
Pathway:
Tyrosine Kinase/Adaptors; Apoptosis
Purity:
0.9808
SMILES:
CC1=C(CC(O)=O)c2cc(F)ccc2C1=C/c1ccc(cc1)S(C)(=O)=O
Target:
Apoptosis; PKA
References
1. Singh T, et al. Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis. Photochem Photobiol. 2012 Sep-Oct;88(5):1141-8.
2. Weight CJ, et al. A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology. 2012 Aug;80(2):484.e17-22.
3. Griffiths GJ. Exisulind Cell Pathways. Curr Opin Investig Drugs. 2000 Nov;1(3):386-91. Review.
4. Lim JT, et al. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3478-84.